Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


LSP announces acquisition of portfolio company FlowCardia, Inc.

Amsterdam and Boston, May 27, 2010 - LSP is pleased to announce that its portfolio company, FlowCardia, Inc., has been acquired by C.R. Bard, Inc. Bard is a worldwide leader in products that focus on disease state management in three key areas: vascular, urology and oncology.

FlowCardia, Inc. which is based in Sunnyvale, CA is a privately held US medical device company established in 2002 to design and manufacture a portfolio of endovascular recanalization products to treat chronic total occlusions (CTOs) in the peripheral and coronary arteries. LSP invested in the company in September 2007 as part of an international syndicate at a time when initial clinical validation of the technology had been accomplished but the market still had to be built. LSP's partner in Boston, Fouad Azzam, joined the supervisory board of the company on behalf of LSP.

Dr. Fouad Azzam, LSP Partner and Director of FlowCardia said, 'This high value sale was the result of FlowCardia's unique products, as well as superior execution of commercial programs by its management team. We congratulate FlowCardia's Chief Executive, Wick Goodspeed, and his entire team for achieving this outstanding result, they combined strong science and flawless execution to achieve this great result. LSP is proud to have been part of the FlowCardia story, whose products will provide significant benefits to both peripheral and coronary patients for the years to come. We wish the entire FlowCardia team continued success with Bard.'

About LSP (
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example, LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.

For more information, please contact:
Dr. Fouad Azzam at + 617 452-1016 or via

Publisher Contact Information:

Life Sciences Partners (LSP)
+ 617 452-1016

Company profile of Life Sciences Partners (LSP)
Past press releases of Life Sciences Partners (LSP).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Mar 16€6.0MInternet commerce
Mar 16€6.2MInternet commerce
Mar 16€5.0MSecurity
Mar 16€3.0MBusiness applications
Mar 16€10.0MBusiness applications
Mar 16€0.8MBusiness applications
Mar 15€6.5MMaterials

For information on Europe's most extensive database on technology funding click here!


Press Releases

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises 37.5 million in series a

Apr 5
logistik-start-up fliit sammelt 1.5 millionen bei seed-finanzierung...

About usContact usLegal Information
Copyright 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.